BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Average Recommendation of “Moderate Buy” from Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS) has received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $32.00.

Several research firms recently issued reports on BLFS. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research report on Monday, December 29th.

Insider Buying and Selling

In related news, Director Amy Duross sold 4,523 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $24.51, for a total transaction of $110,858.73. Following the completion of the transaction, the director owned 25,687 shares in the company, valued at approximately $629,588.37. The trade was a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Greef Roderick De sold 35,417 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $26.15, for a total value of $926,154.55. Following the completion of the transaction, the chief executive officer owned 454,581 shares in the company, valued at approximately $11,887,293.15. The trade was a 7.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 148,005 shares of company stock worth $3,809,067 over the last 90 days. 2.20% of the stock is owned by insiders.

Institutional Trading of BioLife Solutions

Institutional investors have recently modified their holdings of the stock. Amalgamated Bank lifted its position in shares of BioLife Solutions by 3.5% in the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 366 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the period. Louisiana State Employees Retirement System boosted its holdings in shares of BioLife Solutions by 2.9% during the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after purchasing an additional 500 shares during the last quarter. Isthmus Partners LLC grew its position in shares of BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after purchasing an additional 509 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in BioLife Solutions by 2.7% in the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after purchasing an additional 555 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $24.98 on Wednesday. The business’s 50-day moving average is $25.13 and its 200 day moving average is $25.09. BioLife Solutions has a 1 year low of $19.10 and a 1 year high of $29.62. The firm has a market capitalization of $1.20 billion, a P/E ratio of -356.81 and a beta of 1.93.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.